Vaccine efficacy against symptomatic dengue was 65%.
The mosquitoes, captured above Mali and Ghana, were found to be infected with arboviruses, protozoans, and parasitic worms that cause human diseases.
Findings from a phase 3 trial show Qdenga, Takeda's live-attenuated dengue vaccine, provided 61.2% vaccine efficacy against infection and 84.1% against hospitalization after 4.5 years.
Rift Valley fever cases are rising in both people and animals in Senegal and Mauritania.
France and Italy continue to battle chikungunya outbreaks and the spread of dengue, as Greece probes possible local malaria cases.
Rising temperatures, longer summers, milder winters, and changing rainfall patterns are creating more favorable conditions for mosquito populations.
France has now reported 63 local chikungunya cases from 16 different administrative units.
Italy and France are now reporting local chikungunya cases, and 3 countries have confirmed local dengue infections.
Arboviruses are spreading beyond tropical and subtropical regions owing to climate change, population growth, and increased travel, and urbanization.
Recent mosquito-borne illness patterns in Europe reflect the growing geographic spread and public health impact of the diseases.
